Summary
The clinical and laboratory data of 8 patients (4 males and 4 females) with circulating
anticoagulant were presented. Based on prolonged APTT, failure to correct the APTT
with 50 % normal plasma and abnormal tissue thromboplastin inhibition test, the inhibitor
was identified as “middle stage” – or the “lupus anticoagulant”. Thrombokinetics showed
the maximal rate of change in optical density (VmaxΔOD) of plasma, resulting from clot formation to be significantly less in the plasma
of patients with the inhibitor than in normal plasma. This was not completely corrected
by mixing the patients’ plasma with 50% normal plasma.
